Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The recent update from Gilead Sciences and Arcus Biosciences focuses on a Phase 1/1b study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies. The study aims to assess the safety, tolerability, and clinical activity of AB308 combined with zimberelimab (AB122) in treating advanced cancers, highlighting its potential significance in oncology.
The study tests two drugs: AB308 and zimberelimab, both administered intravenously. AB308 is a novel drug, while zimberelimab is an immune checkpoint inhibitor, both intended to treat various advanced malignancies.
This interventional study is non-randomized and follows a sequential intervention model with no masking, focusing on treatment as its primary purpose. Participants receive escalating doses of the drugs in different cohorts to determine optimal dosing and safety.
Key dates include the study’s start on March 19, 2021, and the latest update on June 27, 2025. These dates are crucial for tracking the study’s progress and any emerging data that could impact the market.
The study’s progress could influence Gilead Sciences and Arcus Biosciences’ stock performance, as positive outcomes may boost investor confidence and market position, especially in the competitive oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.